RedShift BioAnalytics Announces Launch of Next Generation Apollo for Ultra-Sensitive Biophysical Characterization of Biomolecules

Apollo, powered by RedShift BioAnalytics’ proprietary MMS technology, incorporates major advances over first-generation AQS³pro to support rapidly growing market demand.

RedShift BioAnalytics (RedShiftBio) announces the launch of Apollo, the company’s latest system using ground-breaking MMS technology. Apollo provides ultra-sensitive, ultra-precise measurements of the structure of biomolecules through a novel technology called Microfluidic Modulation Spectroscopy (MMS), now even more rapidly, with less sample volume, and with improved software and analytics features.

Latest Aithority Insights: Cybersecurity Solutions Provider ActZero Announces Strategic Partnership with TD Synnex

“Apollo represents a tremendous step forward in our product portfolio, incorporating the feedback from our customers at leading biopharmaceutical companies in North America, Europe, and Asia”

MMS overcomes many of the limitations of existing technologies in a typical biophysical characterization toolkit with ultra-sensitive and highly reproducible structural measurements of proteins and other biomolecules. Users are able to compare higher-order structure and similarity profiles for confidence in structural similarity and activity to inform discovery, screening, formulation, and quality control in biopharmaceutical drug development. It can be used for a wide range of biomolecules from mAb-based biotherapeutics to robust measurements of ADCs, AAVs, and mRNA.

Browse The Complete News About Aithority: Proptech Innovator Offerd Unveils Major Upgrades to Multifamily Acquisitions Platform

Key features and benefits of Apollo include:

• Accurate and reproducible measurements with broad concentration range from 0.1 mg/ml to >200 mg/ml allows measurements in native conditions
• 20x faster and 30x more sensitive to changes in structure than CD or FTIR
• Real-time buffer subtraction minimizes background noise and interference from excipients
• Dramatically reduced sample volume requirements from first-generation AQS³pro

“Apollo represents a tremendous step forward in our product portfolio, incorporating the feedback from our customers at leading biopharmaceutical companies in North America, Europe, and Asia,” said Julien Bradley, CEO of RedShiftBio. “The improvements over our first generation AQS³pro system are very significant and will make our already industry-leading tool in biophysical characterization even more valuable and easy to use in a wider range of applications.”

Read More About Aithority News : Loopback Analytics Collaborates with University of Michigan Health on Specialty Pharmacy Initiatives

 [To share your insights with us, please write to sghosh@martechseries.com]